North Carolina gene editing firm signs deal with Pfizer worth up to $1.35B

Triad Business Journal

Jan 11, 2022

Gene-editing firm Beam Therapeutics Inc. has signed a four-year deal worth up to $1.35 billion with pharmaceutical giant Pfizer Inc. Pfizer (NYSE: PFE) is paying Massachusetts-base…